An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Clinical trial NCT01178411 · COMPLETED
Trial details
- NCT number
- NCT01178411
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-31
- Primary completion
- 2019-01-14
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.